| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 05/06/2004 | US20040087552 Pyrrolidine modulators of ccr5 chemokine receptor activity |
| 05/06/2004 | US20040087548 Anticancer agents and treating immune disorders |
| 05/06/2004 | US20040087535 Administering a nitric oxide synthase gene in the form of naked dna; angiogenesis inhibitors |
| 05/06/2004 | US20040087514 Triggering glucagon like peptide 1 secretion; nonglucose carbohydrate and soluble fiber; metabolic syndrome, diabetes, obesity, promotion of satiety |
| 05/06/2004 | US20040087503 Modified ciliary neurotrophic factor (cntf ) with reduced immunogenicity |
| 05/06/2004 | US20040087486 Inhibiting vascular occlusive events; reducing circulating count below normal levels without serious adverse consequence |
| 05/06/2004 | US20040087484 Treating sexual dysfunction associated with hypertension; angiotensin receptor blocker with either antihypertensive agent or HMG-CoA reductase inhibitor |
| 05/06/2004 | US20040087481 Modulation of cholesteryl ester transfer protein (CETP) activity |
| 05/06/2004 | US20040087035 Using myeloproliferative leukemic inhibitory agents to treatment and/ or prevention platelet related thrombotic and vaso-occlusive disorder |
| 05/06/2004 | US20040086988 Enzyme catalyst; polypeptides; crystal structure |
| 05/06/2004 | US20040086942 Comprises peptide mimetic which competes for binding site of immunoglobulin receptor and prevents and treats allergic disorders |
| 05/06/2004 | US20040086940 Novel g protein-coupled receptor protein and dna thereof |
| 05/06/2004 | US20040086905 Lipid-associated molecules |
| 05/06/2004 | US20040086902 Comprises nucleotide sequences coding fructosyltransferase for preparation of fructooligosaccharides and difructose dianhydrides for use as dietetic food or animal feed additive |
| 05/06/2004 | US20040086899 Compromises nuclelotide sequences coding polypeptides associated with elongation of fatty acid chains for treatment and prevention of skin, cardiovascular, inflammatory, gastrointestinal, respiratory system and bone disorders |
| 05/06/2004 | US20040086877 Multi-mode directi memory access controller and method |
| 05/06/2004 | US20040086571 For therapy of dyslipidemia and dyslipoproteinemia |
| 05/06/2004 | US20040086562 Orally administering to a patient a spaced drug delivery system, wherein first therapeutically active agent is released immediately and second therapeutically active agent is released as a pulse at predetermined time after administration |
| 05/06/2004 | US20040086547 By oral administration of beta-glucan soluble fiber and a non-digestible fat |
| 05/06/2004 | US20040086522 Strategies to prevent autoimmune disease by vaccination with vaccines based upon Epstein-Barr virus |
| 05/06/2004 | US20040086521 Method for the identification of antigenic peptides |
| 05/06/2004 | US20040086510 Binds to insulin responsive aminopeptidase or GLUT4 glucose transporter 4 therapeutic agent for treatment or prophylaxis of hyperglycemia or diabetes |
| 05/06/2004 | US20040086505 Derived from human placenta |
| 05/06/2004 | US20040086500 Murabutide, an analog of muramyl dipeptide, induces the production of cytokines or other factors not identified to date, which have a suppressor activity on HIV |
| 05/06/2004 | US20040086485 Viral vector sequences in plasmid form delivered in-vivo to generate vector producing cells |
| 05/06/2004 | EP1416046A1 Use of histamine receptor h3 gene in controlling body weight or food intake |
| 05/06/2004 | EP1415997A1 Polypeptides relating to signal transfer of advanced glycation end product receptor |
| 05/06/2004 | EP1415994A1 Retinal pigmented epithelium derived neurotrophic factor |
| 05/06/2004 | EP1415987A1 Nitrogenous aromatic ring compounds |
| 05/06/2004 | EP1415986A1 Spiro compounds |
| 05/06/2004 | EP1415650A1 Nutritional composition for the prevention and treatment of cachexia and anorexia |
| 05/06/2004 | EP1415005A2 Endogenous retroviruses up-regulated in prostate cancer |
| 05/06/2004 | EP1414964A2 Vegf isoform |
| 05/06/2004 | EP1414963A2 Lipid-associated molecules |
| 05/06/2004 | EP1414961A2 Novel oligoribonucleotide derivatives for the targeted inhibition of gene expression |
| 05/06/2004 | EP1414858A2 Single chain camelid vhh antibodies, method for their production in a mammal, and their uses |
| 05/06/2004 | EP1414856A2 Modified calcitonin |
| 05/06/2004 | EP1414853A2 Method for studying the effects of commensal microflora on mammalian intestine and treatments of gastrointestinal-associated disease based thereon |
| 05/06/2004 | EP1414841A1 Oligonucleotide-containing pharmacological compositions and their use |
| 05/06/2004 | EP1414826A1 Therapeutically useful tetracyclic ligands |
| 05/06/2004 | EP1414825A1 Thienopyrimidinediones and their use in the modulation of autoimmune disease |
| 05/06/2004 | EP1414819A1 THERAPEUTIC 1H-PYRIDO 4,3-b]INDOLES |
| 05/06/2004 | EP1414810A2 1,4-disubstituted benzo-fused cycloalkyl urea compounds |
| 05/06/2004 | EP1414809A1 Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation |
| 05/06/2004 | EP1414806A1 Novel vinyl n-(2-benzoylphenyl)-l-tyrosine derivatives and their use as antidiabetics etc |
| 05/06/2004 | EP1414802A1 Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase |
| 05/06/2004 | EP1414801A1 Arylamines for the treatment of conditions associated with gsk-3 |
| 05/06/2004 | EP1414796A1 Crystalline forms vi and vii of atorvastatin calcium |
| 05/06/2004 | EP1414785A1 Novel vinyl n-(2-benzoylphenyl)-l-tyrosine derivatives and their use as antidiabetics etc |
| 05/06/2004 | EP1414784A2 Amphiphilic star-like macromolecules for drug delivery |
| 05/06/2004 | EP1414778A1 Novel vinyl carboxylic acid derivatives and their use as antidiabetics etc. |
| 05/06/2004 | EP1414522A2 Carbonic anhydrase inhibitors |
| 05/06/2004 | EP1414496A1 Oral pharmaceutical composition containing a combinaition of ppar-alpha and a hmg-coa reductase inhibitor |
| 05/06/2004 | EP1414491A2 Methods of inhibiting amyloid toxicity |
| 05/06/2004 | EP1414487A2 Use of thrombin-derived peptides for the therapy of chronic dermal ulcers |
| 05/06/2004 | EP1414486A2 Use of glp-2 in combination with another therapeutic agent in bone-related and nutrition-related disorders |
| 05/06/2004 | EP1414485A1 Use of corticotroph-derived glycoprotein hormone to induce lipolysis |
| 05/06/2004 | EP1414483A1 Agonists and antagonists of moxifin for the treatment of metabolic disorders |
| 05/06/2004 | EP1414476A1 Bauhinia extracts |
| 05/06/2004 | EP1414474A1 High protein, bowman-birk inhibitor concentrate and process for its manufacture |
| 05/06/2004 | EP1414471A2 Therapeutic agents comprising pro-apoptotic proteins |
| 05/06/2004 | EP1414470A1 Micronutrient phosphates as dietary and health supplements |
| 05/06/2004 | EP1414463A1 Asymmetric synthesis of kavalactones |
| 05/06/2004 | EP1414462A2 Treatment of renal fibrosis |
| 05/06/2004 | EP1414457A1 Chiral dinapsoline |
| 05/06/2004 | EP1414455A1 Isoquinoline inhibitors of p38 |
| 05/06/2004 | EP1414454A1 Paroxetine glycyrrhizinate |
| 05/06/2004 | EP1414450A1 (pyridinyl and pyrimidyl)trienoic acid derivatives as retinoid x receptor modulators |
| 05/06/2004 | EP1414444A1 Novel imidazolidine derivatives, their preparation and their use as vla-4 antagonists |
| 05/06/2004 | EP1414443A1 BENZIMIDAZO 4,5-f]ISOQUINOLINONE DERIVATIVES |
| 05/06/2004 | EP1414442A1 3-arylsulfonyl-7-piperazinyl- indoles, -benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders |
| 05/06/2004 | EP1414440A1 N-phenylpyrrole guanidine derivatives as melanocortin receptor ligands |
| 05/06/2004 | EP1414439A1 Novel pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine |
| 05/06/2004 | EP1414433A1 Improved pharmaceutical composition containing a ppar alpha agent and a process for preparing it |
| 05/06/2004 | EP1414426A1 Carbocyclic hydrazino inhibitors of copper-containing amine oxidases |
| 05/06/2004 | EP1414421A1 The treatment of lipodystrophy |
| 05/06/2004 | EP1414410A1 Nanoparticulate formulations of fenofibrate |
| 05/06/2004 | EP1414316A1 Nutritional composition preventing bacterial overgrowth |
| 05/06/2004 | EP1414314A1 Composition for lowering blood cholesterol |
| 05/06/2004 | EP1268407B1 Propenecarboxylic acid amidoxime derivatives, a process for the preparation thereof, and pharmaceutical compositions containing the same |
| 05/06/2004 | EP1257548B1 Benzofuran carboxamides and their therapeutic use |
| 05/06/2004 | EP1181027B1 Dietary or pharmaceutical composition for use for the prevention or treatment of hyperoxaluria |
| 05/06/2004 | EP1117645B1 Aryl-substituted propanolamine derivatives, methods for their production, medicaments containing said compounds and their use |
| 05/06/2004 | EP1060181B1 Substituted pyrrolobenzimidazoles for treating inflammatory diseases |
| 05/06/2004 | EP0812209B1 Cochleate delivery vehicles for biologically relevant molecules |
| 05/06/2004 | DE10142665B4 C2-Disubstituierte Indan-1-one und ihre Derivate C2-Disubstituted indan-1-one and its derivatives |
| 05/06/2004 | CA2503452A1 N-benzodioxolyl, n-benzodioxanyl and n-benzodioxepinyl arylcarbonxamide derivatives, and pharmaceutical compositions comprising them |
| 05/06/2004 | CA2503405A1 Treating syndrome x with substituted tetralins and indanes |
| 05/06/2004 | CA2503280A1 Allyloxy and allylsulfanyl compounds and use thereof as ppar modulators |
| 05/06/2004 | CA2503276A1 Novel compounds useful in treating ppar mediated diseases |
| 05/06/2004 | CA2503015A1 Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
| 05/06/2004 | CA2502819A1 Inhibitors of glycogen synthase kinase 3 |
| 05/06/2004 | CA2502661A1 Substituted tetralins and indanes |
| 05/06/2004 | CA2502607A1 Method for treating erectile dysfunction and increasing libido in men |
| 05/06/2004 | CA2502118A1 Glp-1 derivatives and transmicosal absorption preparations thereof |
| 05/06/2004 | CA2501677A1 Treatment of diabetes |
| 05/06/2004 | CA2501228A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and type 2 |
| 05/06/2004 | CA2500490A1 Neutralizing antibodies against gdf-8 and uses therefor |
| 05/05/2004 | CN1494593A Modified ciliary neurotrophic factor (CNTF) with reduced immunogenicity |
| 05/05/2004 | CN1494592A Nucleic acid expressed in hypothalamus or muscle tissue in obese animals |